Key Points
- The skin is a viable drug delivery route — used pharmaceutically for decades
- The stratum corneum is the primary barrier — penetration enhancers overcome it
- Transdermal avoids gut degradation and liver first-pass metabolism
- Delivery rate depends on compound molecular weight, lipophilicity, and carrier system
- Berberine, chromium, and EGCG are all suitable candidates for transdermal delivery
The Basics: How Your Skin Absorbs Compounds
The skin is the body's largest organ — approximately 2 square metres in adults — and it serves as both a protective barrier and a selective gateway. While its primary function is to keep things out, pharmaceutical science has exploited its absorption properties for decades: nicotine patches, hormone patches, fentanyl patches, and nitroglycerine patches are all mainstream pharmaceutical products delivered transdermally.
Transdermal delivery works by placing a high concentration of a compound against the skin's outer surface. The concentration gradient between the patch and the skin drives diffusion — compounds move from the high-concentration reservoir in the patch into the lower-concentration tissue beneath. Once through the outer skin layers, compounds enter the capillary network in the dermis and pass directly into systemic circulation.
The Stratum Corneum: The Main Challenge
The primary barrier to transdermal delivery is the stratum corneum — the outermost layer of the skin, approximately 10–20 micrometres thick. It consists of dead, flattened keratinocytes embedded in a lipid matrix that functions like a brick-and-mortar structure: highly effective at blocking water and most environmental chemicals.
For pharmaceutical transdermal delivery to work, compounds must either be naturally lipophilic enough to dissolve in this lipid matrix (as nicotine and fentanyl are) or be assisted by chemical penetration enhancers that temporarily disrupt the lipid structure and allow less lipophilic compounds through.
The three routes through skin
Transcellular: Directly through skin cells — requires high lipophilicity.
Intercellular: Through the lipid channels between cells — the primary route for most
compounds with penetration enhancers.
Appendageal: Via hair follicles and sweat glands — limited area (~0.1% of skin surface) but
useful for larger molecules.
Penetration Enhancers: How Non-Lipophilic Compounds Are Delivered
The Duori GLP-1 Support Patch uses a medical-grade adhesive carrier system with chemical penetration enhancers — specifically oleic acid and propylene glycol. These work through complementary mechanisms:
Oleic acid is a fatty acid that intercalates into the lipid bilayer of the stratum corneum, creating disorganised domains that increase membrane fluidity and permeability. It is one of the most studied and effective penetration enhancers in pharmaceutical transdermal formulation.
Propylene glycol acts both as a co-solvent (improving compound solubility in the patch reservoir) and as a penetration enhancer (disrupting keratin structure in the stratum corneum). The combination of oleic acid and propylene glycol is a validated pharmaceutical approach used in multiple approved transdermal drug products.
Why Berberine Is a Good Transdermal Candidate
Not all compounds are equally suitable for transdermal delivery. The key factors are molecular weight (under ~500 daltons is preferred), lipophilicity (log P between 1–3 is optimal), and the absence of compounds that would be degraded by skin enzymes.
Berberine has a molecular weight of 336 daltons — well within the preferred range. Its moderate lipophilicity makes it compatible with both the lipid-rich stratum corneum environment and the aqueous tissue beneath. Combined with appropriate penetration enhancers, berberine absorption through the skin has been validated in pharmacokinetic research, with transdermal delivery producing more consistent systemic levels than oral supplementation.
Why Transdermal Wins for Weight Support Compounds
The three primary advantages of transdermal delivery for metabolic compounds like berberine, chromium, and EGCG are:
- Bypasses gut degradation: Oral berberine is significantly degraded by gut bacteria before absorption. Transdermal delivery skips this entirely.
- Bypasses first-pass metabolism: Compounds absorbed from the gut go directly to the liver before systemic circulation. Transdermal compounds enter circulation via capillaries in the dermis, bypassing the liver entirely.
- Sustained release profile: A patch delivers compounds at a controlled rate over hours rather than producing the acute peak-and-crash of a capsule dose. For metabolic compounds where cumulative AMPK activation matters, sustained delivery outperforms acute dosing.
Transdermal delivery applied to weight management
The Duori GLP-1 Support Patch. Medical-grade adhesive carrier. 8-hour sustained release. $24 / 30-day supply.
Frequently Asked Questions
* These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.